The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, discusses results from the new analysis of the Phase III NALA study investigating neratinib plus capecitabine versus lapatinib plus capecitabine in patients with third-line HER2+ metastatic breast cancer who entered the trial with central nervous system (CNS) metastases
Tags: BreastSABCS Conference Coverage
Published: 17 December 2020
Kevin Kalinsky, MD, summarizes recent clinical data regarding the role of CDK 4/6 inhibitors
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, summarizes some recent clinical data regarding CDK 4/6 inhibitors and their expanding role in the management of early and late stage breast cancer
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, summarizes some recent clinical data regarding CDK 4/6 ...
Kevin Kalinsky, MD, shares thoughts on the DESTINY-Breast01 clinical trial from SABCS 2020
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares thoughts on the DESTINY-Breast01 clinical trial investigating trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer who had received at least two lines of anti-HER2 based therapies
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares thoughts on the DESTINY-Breast01 clinical trial investigating ...
Kevin Kalinsky, MD, regarding CTCs as a predictor of overall survival in metastatic breast cancer
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, considers the role of circulating tumor cells (CTCs) as a predictor of overall survival in patients with metastatic breast cancer based on presentations from SABCS 2020
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, considers the role of circulating tumor cells (CTCs) ...
Kevin Kalinsky, MD, offers considerations when treating patients with HR+, HER2- breast cancer
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares what the hematologist/oncologist community should know regarding how we treat patients with HR+, HER2- breast cancer that has spread to 1-3 lymph nodes
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares what the hematologist/oncologist community should know regarding ...
Kevin Kalinsky, MD, considers the practice-changing potential of RxPONDER
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, offers opinion on whether results from the RxPONDER clinical trial presented at the 2020 San Antonio Breast Cancer Symposium are practice changing
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, offers opinion on whether results from the RxPONDER ...
Kevin Kalinsky, MD, shares impressions of the RxPONDER clinical trial presented at SABCS 2020
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares impressions of the RxPONDER clinical trial presented at the 2020 San Antonio Breast Cancer Symposium and considers whether genomic tumor tissue tests can determine the necessity of chemotherapy
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares impressions of the RxPONDER clinical trial presented ...
Priya Rastogi, MD, on key takeaways for oncologists regarding the tolerability of CDK 4/6 inhibitors
Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares key takeaways for oncologists regarding the tolerability of CDK 4/6 inhibitors
Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares key ...
Adam Brufsky, MD, PhD, elaborates on the clinical implications of DESTINY-Breast01 from SABCS 2020
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, elaborates on the clinical implications of the DESTINY-Breast01 study investigating trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, elaborates ...
Priya Rastogi, MD, provides details on the subgroup of patients with Ki-67 status from monarchE
Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares thoughts on the subgroup of patients with Ki-67 status involved the monarchE clinical trial from SABCS 2020
Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares thoughts ...
Adam Brufsky, MD, PhD, discusses the issue of resistance to HER2-targeted therapy
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, discusses the issue of resistance to HER2-targeted therapy
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, discusses ...
Kevin Kalinsky, MD, summarizes recent clinical data regarding the role of CDK 4/6 inhibitors
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, summarizes some recent clinical data regarding CDK 4/6 inhibitors and their expanding role in the management of early and late stage breast cancer
Kevin Kalinsky, MD, shares thoughts on the DESTINY-Breast01 clinical trial from SABCS 2020
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares thoughts on the DESTINY-Breast01 clinical trial investigating trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer who had received at least two lines of anti-HER2 based therapies
Kevin Kalinsky, MD, regarding CTCs as a predictor of overall survival in metastatic breast cancer
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, considers the role of circulating tumor cells (CTCs) as a predictor of overall survival in patients with metastatic breast cancer based on presentations from SABCS 2020
Kevin Kalinsky, MD, offers considerations when treating patients with HR+, HER2- breast cancer
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares what the hematologist/oncologist community should know regarding how we treat patients with HR+, HER2- breast cancer that has spread to 1-3 lymph nodes
Kevin Kalinsky, MD, considers the practice-changing potential of RxPONDER
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, offers opinion on whether results from the RxPONDER clinical trial presented at the 2020 San Antonio Breast Cancer Symposium are practice changing
Kevin Kalinsky, MD, shares impressions of the RxPONDER clinical trial presented at SABCS 2020
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares impressions of the RxPONDER clinical trial presented at the 2020 San Antonio Breast Cancer Symposium and considers whether genomic tumor tissue tests can determine the necessity of chemotherapy
Priya Rastogi, MD, on key takeaways for oncologists regarding the tolerability of CDK 4/6 inhibitors
Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares key takeaways for oncologists regarding the tolerability of CDK 4/6 inhibitors
Adam Brufsky, MD, PhD, elaborates on the clinical implications of DESTINY-Breast01 from SABCS 2020
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, elaborates on the clinical implications of the DESTINY-Breast01 study investigating trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer
Priya Rastogi, MD, provides details on the subgroup of patients with Ki-67 status from monarchE
Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares thoughts on the subgroup of patients with Ki-67 status involved the monarchE clinical trial from SABCS 2020
Adam Brufsky, MD, PhD, discusses the issue of resistance to HER2-targeted therapy
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, discusses the issue of resistance to HER2-targeted therapy
Priya Rastogi, MD, considers the interchangeability of CDK 4/6 inhibitors
Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, on whether certain CDK 4/6 inhibitors are interchangeable in the management of HR+, HER2- node positive high risk early breast cancer
Adam Brufsky, MD, PhD, describes the treatment landscape of HER2+ metastatic breast cancer
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, describes the treatment landscape of HER2+ metastatic breast cancer and speculates on emerging novel agents
Priya Rastogi, MD, elaborates on the role of abemaciclib in HR+, HER2- node positive breast cancer
Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, discusses the standard of care for patients with HR+, HER2- node positive high risk early breast cancer and the role of abemaciclib in this group of patients
Adam Brufsky, MD, PhD, considers the investigation of poziotinib in HER2+ metastatic breast cancer
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, considers the ongoing investigation of poziotinib in patients with HER2+ metastatic breast cancer heavily pre-treated with HER2-targeted therapy
Priya Rastogi, MD, shares the design and outcomes of the monarchE clinical trial from SABCS 2020
Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares the design and outcomes of the monarchE clinical trial investigating abemaciclib in combination with adjuvant endocrine therapy in patients with HR+, HER2− early breast cancer (EBC) presented at the 2020 San Antonio Breast Cancer Symposium
Hope Rugo, MD, provides perspective on the clinical progress of CDK 4/6 inhibitors in breast cancer
Dr. Rugo, Director of Breast Oncology and Clinical Trials Education, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, provides perspective on the clinical progress of CDK 4/6 inhibitors in early breast cancer as presented at the 2020 San Antonio Breast Cancer Symposium
Hope Rugo, MD, examines data from the DESTINY-Breast01 clinical study presented at SABCS 2020
Dr. Rugo, Director of Breast Oncology and Clinical Trials Education, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, shares thoughts on the DESTINY-Breast01 clinical study investigating trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer who had received at least two lines of anti-HER2 based therapies
Hope Rugo, MD, offers key takeaways for physicians regarding KEYNOTE-355
Dr. Rugo, Director of Breast Oncology and Clinical Trials Education, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, offers key takeaways for physicians regarding KEYNOTE-355 investigating pembrolizumab in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple‑negative breast cancer whose tumors express PD-L1 (CPS ≥10) as presented at the 2020 San Antonio Breast Cancer Symposium
Hope Rugo, MD, considers chemotherapy recommendations based on findings from KEYNOTE-355
Dr. Rugo, Director of Breast Oncology and Clinical Trials Education, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, offers opinion on the type of chemotherapy recommended for patients with locally recurrent unresectable or metastatic triple‑negative breast cancer whose tumors express PD-L1 (CPS ≥10) based on findings from KEYNOTE-355
Hope Rugo, MD, shares the design and outcomes of KEYNOTE-355 presented at SABCS 2020
Dr. Rugo, Director of Breast Oncology and Clinical Trials Education, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, shares the design and outcomes of KEYNOTE-355 investigating pembrolizumab in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple‑negative breast cancer whose tumors express PD-L1 (CPS ≥10)
Hope Rugo, MD, considers the incidence of TNBC and what makes this disease so difficult to treat
Dr. Rugo, Director of Breast Oncology and Clinical Trials Education, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, considers the incidence of triple-negative breast cancer (TNBC) and what makes this disease so difficult to treat
Erika Hamilton, MD, considers the role of NGS testing for breast cancer patients
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, considers the role of next-generation sequencing (NGS) for breast cancer patients
Erika Hamilton, MD, regarding the use of CDK 4/6 inhibitors in clinical practice
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, regarding the use of CDK 4/6 inhibitors in clinical practice
Erika Hamilton, MD, on promising treatment options in the management of HER2+ advanced breast cancer
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, speculates on promising treatment options in the management of HER2+ advanced breast cancer
Erika Hamilton, MD, provides perspective on the latest immunotherapy treatment trends in TNBC
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, provides perspective on the latest immunotherapy treatment trends in triple-negative breast cancer (TNBC)
Erika Hamilton, MD, discusses findings from the MARIO-3 clinical trial presented at the 2020 SABCS
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses findings from the MARIO-3 Phase II study investigating a novel triplet in first-line triple negative breast cancer (TNBC) presented at the 2020 San Antonio Breast Cancer Symposium
Debra Patt, MD, PhD, MBA, speculates on exciting data in TNBC coming out of SABCS 2020
Dr. Patt, Executive Vice President, Texas Oncology, speculates on exciting data in triple-negative breast cancer (TNBC) coming out of the 2020 San Antonio Breast Cancer Symposium
Debra Patt, MD, PhD, MBA, summarizes data from the ExteNET trial presented at SABCS 2020
Dr. Patt, Executive Vice President, Texas Oncology, discusses the overall survival analysis from the ExteNET trial, investigating neratinib in HER2-positive patients presented at the 2020 San Antonio Breast Cancer Symposium
Debra Patt, MD, PhD, MBA, comments on findings from the KEYNOTE-355 trial
Dr. Patt, Executive Vice President, Texas Oncology, comments on findings from the KEYNOTE-355 trial presented at the 2020 San Antonio Breast Cancer Symposium
Debra Patt, MD, PhD, MBA, provides perspective on the latest immunotherapy treatment trends in TNBC
Dr. Patt, Executive Vice President, Texas Oncology, provides perspective on the latest immunotherapy treatment trends in triple-negative breast cancer (TNBC)
Debra Patt, MD, PhD, MBA, on the promising investigations of CDK4/6 inhibitors
Dr. Patt, Executive Vice President, Texas Oncology, offers opinion on promising research regarding the use of CDK4/6 inhibitors
Julie Gralow, MD, offers opinion on immunotherapy treatment trends in the management of TNBC
Dr. Gralow, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Jill Bennett Endowed Professor of Breast Oncology, University of Washington, offers opinion on the latest immunotherapy treatment trends in the management of triple-negative breast cancer (TNBC)
Julie Gralow, MD, regarding the ITOMIC trial data from the 2020 San Antonio Breast Cancer Symposium
Dr. Gralow, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Jill Bennett Endowed Professor of Breast Oncology, University of Washington, shares results from the ITOMIC trial presented at the 2020 San Antonio Breast Cancer Symposium
Julie Gralow, MD, elaborates on the issue of resistance to endocrine therapies
Dr. Gralow, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Jill Bennett Endowed Professor of Breast Oncology, University of Washington, elaborates on the issue of resistance to endocrine therapies
Julie Gralow, MD, summarizes the RxPONDER trial from the 2020 San Antonio Breast Cancer Symposium
Dr. Gralow, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Jill Bennett Endowed Professor of Breast Oncology, University of Washington, tells us about the RxPONDER trial presented at the 2020 San Antonio Breast Cancer Symposium
Julie Gralow, MD, provides details on the SWOG S0226 findings presented at SABCS 2020
Dr. Gralow, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Jill Bennett Endowed Professor of Breast Oncology, University of Washington, discusses results from SWOG S0226, investigating serum thymidine kinase 1 (TK1) in HR+ metastatic breast cancer
Elizabeth Mittendorf, MD, PhD, discusses the outcomes of the IMpassion-031 study
Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, discusses the outcomes of the IMpassion-031 study investigating the neoadjuvant use of atezolizumab plus chemotherapy in early triple-negative breast cancer (TNBC)
Elizabeth Mittendorf, MD, PhD, on the implications of the IMpassion-130 and IMpassion-131 trials
Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, on how we might reconcile the outcomes of the IMpassion-130 and IMpassion-131 clinical trials and what these trials mean for the treatment of metastatic triple-negative breast cancer (TNBC)
Elizabeth Mittendorf, MD, PhD, considers key takeaways from the Impassion-131 presented at ESMO 2020
Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, considers key takeaways from the Impassion-131 clinical trial investigating first-line atezolizumab in combination with chemotherapy in metastatic triple-negative breast cancer (TNBC) presented at the 2020 ESMO Virtual Congress
Elizabeth Mittendorf, MD, PhD, discusses the IMpassion-130 clinical trial presented at ESMO 2020
Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, discusses the long-term overall survival analysis of the IMpassion-130 clinical trial investigating the atezolizumab and nab paclitaxel combination in triple negative metastatic breast cancer (TNBC) patients presented at the 2020 ESMO Virtual Congress
Aditya Bardia, MD, MPH, considers the practice-changing potential of the ASCENT study from ESMO 2020
Dr. Bardia, Assistant Professor of Medicine, Harvard Medical School, Attending Physician, Medical Oncology, Massachusetts General Hospital, speculates on whether the Phase III ASCENT study investigating sacituzumab govitecan in triple negative breast cancer (TNBC) is practice-changing in this hard to treat group of patients
Aditya Bardia, MD, MPH, describes the outcomes from the Phase III ASCENT study from ESMO 2020
Dr. Bardia, Assistant Professor of Medicine, Harvard Medical School, Attending Physician, Medical Oncology, Massachusetts General Hospital, describes the outcomes from the Phase III ASCENT study investigating sacituzumab govitecan in triple negative breast cancer (TNBC) patients
Aditya Bardia, MD, MPH, discusses the design of newly approved sacituzumab govitecan
Dr. Bardia, Assistant Professor of Medicine, Harvard Medical School, Attending Physician, Medical Oncology, Massachusetts General Hospital, discusses the design of newly approved sacituzumab govitecan and why this type of compound is effective in historically difficult to treat breast cancer
Erika Hamilton, MD, shares thoughts on tolerability in high risk early breast cancer patients
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, shares thoughts on the tolerability of abemaciclib added to hormonal therapy in high risk early breast cancer patients
Erika Hamilton, MD, considers the comparison between the monarchE and PALLAS clinical trials
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, considers the comparison between the monarchE and PALLAS clinical trials and why there is a difference in outcomes in the two adjuvant breast cancer studies
Erika Hamilton, MD, considers the significance of the MonarchE study & the use of abemaciclib
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, considers the impact of the monarchE study investigating the addition of abemaciclib to hormonal therapy in patients with high-risk HR+, HER2- early breast cancer as presented at ESMO20 and whether should abemaciclib should be widely adopted for use in this setting
Erika Hamilton, MD, regarding the Phase III monarchE trial presented at ESMO 2020
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the results of the Phase III monarchE trial investigating the addition of abemaciclib to hormonal therapy in patients with high-risk HR+, HER2- early breast cancer presented at the 2020 ESMO Virtual Congress
Erika Hamilton, MD, on how CDK4/6 inhibitors transformed the management of metastatic breast cancer
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, explains how CDK4/6 inhibitors have transformed the management of metastatic breast cancer
Erika Hamilton, MD, on the standard of care for high-risk early HR+, HER2- breast cancer
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, considers the effectiveness of the current standard of care for the adjuvant treatment of patients with high-risk early HR+, HER2- breast cancer
Sara Hurvitz, MD, describes the recently reported results using PARP inhibition and cisplatin
Dr. Hurvitz, Associate Professor, David Geffen School of Medicine, describes the recently reported results using PARP inhibition with and without cisplatin to treat advanced breast cancer with HRD (homologous repair deficiencies)
Sara Hurvitz, MD, discusses the recently announced results of Monarch E and PALLAS adjuvant trials
Dr. Hurvitz, Associate Professor, David Geffen School of Medicine, discusses the recently announced results of both the Monarch E and PALLAS adjuvant trials in early stage high risk hormone receptor positive breast cancer
Sara Hurvitz, MD, shares design and outcomes of the HER2CLIMB study in advanced breast cancer
Dr. Hurvitz, Associate Professor, David Geffen School of Medicine, shares the design and outcomes of the HER2CLIMB study investigating tucatinib in advanced breast cancer
Debu Tripathy, MD, describes the evolving role of PARP inhibitors in breast cancer patients
Dr. Tripathy, Chair, Breast Medical Oncology, MD Anderson Cancer Center, describes the evolving role of PARP inhibitors in breast cancer patients exhibiting germline or somatic abnormalities in BRCA or HRD genes
Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20
Dr. Tripathy, Chair, Breast Medical Oncology, MD Anderson Cancer Center, introduces new information regarding CDK4/6 inhibitors for hormone receptor positive breast cancer discussed at ASCO20
Debu Tripathy, MD, on presentations pertaining to immunotherapy in early breast cancer treatment
Dr. Tripathy, Chair, Breast Medical Oncology, MD Anderson Cancer Center, reports on presentations presented at ASCO20 pertaining to immunotherapy in the treatment of early breast cancer
Debu Tripathy, MD, discusses recent FDA approvals and HER2+ metastatic breast cancer management
Dr. Tripathy, Chair, Breast Medical Oncology, MD Anderson Cancer Center, provides his perspective on tucatinib and the HER2CLIMB study presented at ASCO20 and trastuzumab deruxtecan (Enhertu) for HER2+ MBC patients
Nancy Lin, MD, on impressions of the Phase 2 study done the by the Translational Breast Cancer Consortium
Dr. Lin, Associate Chief, Susan F. Smith Center for Women's Cancers, discusses impressions of the Phase 2 study done by the Translational Breast Cancer Consortium investigating olaparib in metastatic breast cancer patients with the BRCA1 or BRCA2 mutation and presented at ASCO20
Nancy Lin, MD, explores the role of CDK4/6 inhibitors in metastatic breast cancer management
Dr. Lin, Associate Chief, Susan F. Smith Center for Women's Cancers, explores the role of CDK4/6 inhibitors today in the management of HR+, HER2- metastatic breast cancer and whether the PALLAS results impact the way metastatic patients are treated
Nancy Lin, MD, discusses the standard of care when adjuvant treating HR+, HER2- early breast cancer
Dr. Lin, Associate Chief, Susan F. Smith Center for Women's Cancers, discusses the standard of care for the adjuvant treatment of HR+, HER2- early breast cancer patients given the negative outcomes of the PALLAS study
Nancy Lin, MD, provides perspective on the global Phase 3 PALLAS trial regarding early breast cancer
Dr. Lin, Associate Chief, Susan F. Smith Center for Women's Cancers, provides perspective on the global Phase 3 PALLAS trial testing the addition of 2 years of palbociclib to standard adjuvant endocrine therapy in HR+, HER2- early breast cancer patients
Nancy Lin, MD, considers whether the results of the HER2CLIMB study will become a new care standard
Dr. Lin, Associate Chief, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, considers the results of the HER2CLIMB study and if tucatinib in combination with T and C should become a new standard of care for heavily treated metastatic breast cancer patients with brain metastases.
Nancy Lin, MD, on the design and outcomes of the HER2CLIMB study regarding metastatic breast cancer
Dr. Lin, Associate Chief, Susan F. Smith Center for Women's Cancers, shares the design and outcomes of the HER2CLIMB study investigating tucatinib in combination with T and C in patients with heavily treated metastatic breast cancer with brain metastases
Karen Lu, MD, illustrates challenges the MAGENTA study brings up associated with genetic counseling
Dr. Lu, Professor and Chair, MD Anderson Cancer Center, illustrates challenges the MAGENTA study brings up associated with genetic counseling
Karen Lu, MD, provides opinion on whether genetic counseling should be part of the SOP for breast and ovarian cancer risk
Dr. Lu, Professor and Chair, MD Anderson Cancer Center, provides opinion on whether genetic counseling should be part of the SOP when trying to identify people at risk for breast and ovarian cancer,
Karen Lu, MD, shares outcomes of the MAGENTA study investigating the role of genetic counseling
Dr. Lu, Professor and Chair, MD Anderson Cancer Center, shares outcomes of the MAGENTA study which investigates the role of genetic counseling as it relates to online testing for breast and ovarian cancer genetic risk
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.